Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)

Published on Oct 1, 2018in Pancreatology3.629
· DOI :10.1016/J.PAN.2018.07.007
Junki Mizusawa36
Estimated H-index: 36
Akira Fukutomi22
Estimated H-index: 22
+ 11 AuthorsHepatobiliary3
Estimated H-index: 3
Abstract Gemcitabine is one of the standard treatments for locally advanced pancreatic cancer. Recent studies on metastatic pancreatic cancer have shown that combination chemotherapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel (GnP) prolonged the overall survival compared with gemcitabine alone. To select the most promising chemotherapy, a randomized phase II selection design trial was started in July 2016 to compare between modified FOLFIRINOX and GnP for patients with locally advanced pancreatic cancer. A total of 124 patients will be enrolled from 36 Japanese institutions within 2.5 years. The primary endpoint is the proportion of 1-year overall survival, and secondary endpoints are progression-free survival, distant metastasis-free survival, response rate in patients with target lesions, CA19-9 response, adverse events, treatment-related death, early death, grade 4 non-hematological toxicity, and dose intensity. This trial has been registered with the UMIN Clinical Trials Registry [ ], and the registration number is UMIN000023143.
📖 Papers frequently viewed together
3,500 Citations
#1Tatsuya IokaH-Index: 27
#2Akira FukutomiH-Index: 22
Last. J. FuruseH-Index: 11
view all 20 authors...
3 CitationsSource
#1Makoto UenoH-Index: 21
#2Masato Ozaka (JFCR: Japanese Foundation for Cancer Research)H-Index: 14
Last. Junji Furuse (Kyorin University)H-Index: 62
view all 12 authors...
Background We evaluated the efficacy and safety of a modified FOLFIRINOX regimen for chemotherapy-naive patients with metastatic pancreatic cancer.
10 CitationsSource
#1Hideki UenoH-Index: 67
#2Masafumi IkedaH-Index: 51
Last. Junji Furuse (Kyorin University)H-Index: 62
view all 8 authors...
Purpose Efficacy and safety of nab-paclitaxel plus gemcitabine have not been clarified in Japanese patients with metastatic pancreatic cancer. No pharmacokinetic profile of co-administration of nab-paclitaxel and gemcitabine has been reported. We conducted a phase I/II study of the efficacy, safety, and pharmacokinetics in Japanese patients with metastatic pancreatic cancer.
80 CitationsSource
#1Takuji OkusakaH-Index: 76
#2Masafumi IkedaH-Index: 51
Last. Narikazu Boku (St. Marianna University School of Medicine)H-Index: 66
view all 8 authors...
The FOLFIRINOX combination of chemotherapy drugs had not been fully evaluated for Japanese pancreatic cancer patients. Therefore, we carried out a phase II study to examine the efficacy and safety of FOLFIRINOX in chemotherapy-naive Japanese patients with metastatic pancreatic cancer. FOLFIRINOX (i.v. infusion of 85 mg/m2 oxaliplatin, 180 mg/m2 irinotecan, and 200 mg/m2 l-leucovorin, followed by a bolus of 400 mg/m2 fluorouracil and a 46-h continuous infusion of 2400 mg/m2 fluorouracil) was give...
92 CitationsSource
#1Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 89
#2Thomas J. ErvinH-Index: 30
Last. Abstr ActH-Index: 53
view all 23 authors...
BACKGROUND In a phase 1–2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. METHODS We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performan...
3,500 CitationsSource
#1Hideki UenoH-Index: 67
#2Tatsuya IokaH-Index: 27
Last. Masao Tanaka (Kyushu University)H-Index: 105
view all 25 authors...
Purpose The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival. Patients and Methods The participants were chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface a...
421 CitationsSource
#1Junji Furuse (Kyorin University)H-Index: 62
#2Hiroshi IshiiH-Index: 21
Last. Takuji OkusakaH-Index: 76
view all 3 authors...
The Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG) was constituted in April 2008 to develop new standard treatments for hepatobiliary and pancreatic cancer. In pancreatic cancer, the Hepatobiliary and Pancreatic Oncology Group focuses on establishing standard chemotherapy or chemoradiotherapy for unresectable locally advanced disease. The JCOG 0506 study was a Phase II study of gemcitabine alone to examine its efficacy and safety in patients with locally ...
4 CitationsSource
BackgroundData are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. MethodsWe randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxa...
4,409 CitationsSource
#1Hiroshi IshiiH-Index: 21
#2Junji Furuse (Kyorin University)H-Index: 62
Last. Haruhiko FukudaH-Index: 50
view all 10 authors...
Objective: Chemoradiotherapy with 5-fluorouracil has been accepted as a standard care for locally advanced pancreatic cancer; however, it has not been shown to be superior to chemotherapy alone in the gemcitabine era. The present multicentre phase II study was conducted to evaluate the efficacy and safety of Gem monotherapy against locally advanced pancreatic cancer in comparison with the historical data of chemoradiotherapy with 5-fluorouracil. Methods: Eligibility criteria included patients wi...
57 CitationsSource
#1Elizabeth A. Eisenhauer (Queen's University)H-Index: 69
#2P. Therasse (GSK: GlaxoSmithKline)H-Index: 13
Last. Denis Lacombe (European Organisation for Research and Treatment of Cancer)H-Index: 52
view all 16 authors...
Abstract Background Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to th...
15.2k CitationsSource
Cited By14
#1Ning Pu (Fudan University)H-Index: 10
#2Hanlin Yin (Fudan University)H-Index: 5
Last. Wenhui Lou (Fudan University)H-Index: 20
view all 6 authors...
Pancreatic cancer is one of the most aggressive diseases in the world due to a lack of early detection, leading to an overall 5-year survival of only 10%. In recent years, clinical trials targeted pancreatic cancer in efforts to improve survival. These studies introduce new technologies, concepts, and evidence which have instilled new optimism for improving prognosis. This review summarizes the current status of the recent (5-year) clinical trials and describes contemporary research on pancreati...
view all 3 authors...
#1Isabella FrigerioH-Index: 17
#2Salvatore PaiellaH-Index: 23
Last. G. FiorentiniH-Index: 14
view all 22 authors...
Abstract null null Background null Local ablation of pancreatic cancer has been suggested as an option to manage locally advanced pancreatic cancer (LAPC) although no robust evidence has been published to date to support its application. The aim of this study is to compare overall survival (OS) and progression-free survival (PFS) in patients receiving both radiofrequency ablation (RFA) and conventional chemoradiotherapy (CHRT) with patients receiving CHRT only. null null null Methods null This i...
Background: Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX (FFX) are two standard first-line therapies for metastatic pancreatic cancer (PC) but have rarely been compared, especially in patients with locally advanced PC (LAPC). Methods: This is a retrospective European multicenter study including patients with LAPC treated with either GN or FFX as the first-line therapy between 2010 and 2019. Coprimary objectives were progression-free survival (PFS) and overall survival (OS), both estimated usin...
2 CitationsSource
#1Tsuyoshi Takeda (JFCR: Japanese Foundation for Cancer Research)H-Index: 3
#2Takashi Sasaki (JFCR: Japanese Foundation for Cancer Research)H-Index: 7
Last. Naoki Sasahira (JFCR: Japanese Foundation for Cancer Research)H-Index: 6
view all 9 authors...
BACKGROUND The prognostic impact of tumour location (pancreatic head vs. pancreatic body/tail) and first-line chemotherapy regimen (gemcitabine plus nab-paclitaxel vs. modified FOLFIRINOX) has not been fully elucidated in locally advanced pancreatic cancer. Therefore, we conducted this study to examine the prognostic impact of tumour location and first-line chemotherapy regimen. METHODS We retrospectively investigated locally advanced pancreatic cancer patients who initiated first-line chemother...
#1Hiroki Sato (Asahikawa Medical University)H-Index: 4
#2Takuma Goto (Asahikawa Medical University)H-Index: 5
Last. Toshikatsu Okumura (Asahikawa Medical University)H-Index: 40
view all 14 authors...
Abstract Background/objectives Decrease in skeletal muscle mass and function is associated with a poor prognosis following surgical resection of pancreatic ductal adenocarcinomas (PDAs). This study evaluated whether skeletal muscle mass decrease affects PDA outcomes. Methods Data of 112 patients with advanced and unresectable PDA who underwent chemotherapy in a single institution were retrospectively analyzed. Information on age, sex, hematological investigations, including systemic inflammation...
#1M.S. Walma (UvA: University of Amsterdam)H-Index: 1
#2Lilly J Brada (UvA: University of Amsterdam)H-Index: 1
Last. I. Quintus MolenaarH-Index: 31
view all 44 authors...
Abstract Introduction Since current studies on locally advanced pancreatic cancer (LAPC) mainly report from single, high-volume centers, it is unclear if outcomes can be translated to daily clinical practice. This study provides treatment strategies and clinical outcomes within a multicenter cohort of unselected patients with LAPC. Materials and methods Consecutive patients with LAPC according to Dutch Pancreatic Cancer Group criteria, were prospectively included in 14 centers from April 2015 un...
2 CitationsSource
#1Shintaro NakanoH-Index: 1
#2Yoshito KomatsuH-Index: 33
Last. Naoya SakamotoH-Index: 62
view all 8 authors...
It is unclear whether the use of antibiotics is related to the efficacy of gemcitabine plus nab-paclitaxel (GnP). Therefore, we investigated the association between the use of antibiotics and efficacy of GnP.We conducted a retrospective single center study from January 2014 to December 2018 in Hokkaido University Hospital.Ninety-nine patients were eligible for the study. Thirty-seven used antibiotics (U) and 62 did not use antibiotics (NU) during GnP therapy. In the U group, 15 patients used β-l...
3 CitationsSource
#1Deepanshi Dhar (UM: University of Montana)H-Index: 7
#2Komal Raina (UM: University of Montana)H-Index: 30
Last. Rajesh Agarwal (UM: University of Montana)H-Index: 104
view all 10 authors...
Chemoresistance to gemcitabine (GEM)-a frontline chemotherapeutic, resulting from its dysfunctional uptake and metabolism in cancer cells, is a major contributing factor for failed therapy in pancreatic cancer (PanC) patients. Therefore, there is an urgent need for agents that could reverse GEM resistance and allow continued chemosensitivity to the drug. We employed natural nontoxic agent (with anti-PanC potential) bitter melon juice (BMJ) and GEM to examine their combinatorial benefits against ...
1 CitationsSource
The prognosis of patients with pancreatic cancer continues to remain dismal, even though numerous trials have been conducted to establish more effective therapies in Japan and throughout the world. Recent advances in treatment have been characterized by the use of novel combinations of conventional cytotoxic chemotherapies. Especially in Japan, S-1 has become one of the most widely used cytotoxic agents for the treatment of pancreatic cancer, after clinical evidence was established of the surviv...
9 CitationsSource